Xarelto's Efficacy Impresses In ACS, But Bleeding Risk Will Complicate Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer/Johnson & Johnson's rivaroxaban demonstrated a significant reduction in the risk of major adverse cardiovascular events, but it also significantly increased the risk of major bleeding in the Phase III ATLAS trial of acute coronary syndrome patients.
You may also be interested in...
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
Pradaxa Almost Clear Of NICE Hurdle
Boehringer Ingelheim has answered all of NICE's questions on Pradaxa, meaning it is on the brink of being used in the NHS.